

( (S (NP-SBJ The Supreme Court)
     (VP let
         (S (VP stand)
	    (NP-SBJ (NP a New York court 's)
		    ruling
		    (SBAR that
			  (S (NP-SBJ (NP the manufacturers)
				     (PP of
					 (NP (NP a drug)
					     (VP (ADVP-TMP once)
						 used
						 (NP *)
						 (S-CLR (NP-SBJ *)
							(VP to
							    (VP prevent
								(NP miscarriages))))))))
			     (VP must
				 (VP share
				     (NP (NP liability)
					 (PP for
					     (NP injuries or deaths)))
				     (SBAR (WHADVP-1 when)
					   (S (NP-SBJ (NP the maker)
						      (PP of
							  (NP an individual dose)))
					      (VP is
						  (ADJP-PRD unknown)
						  (ADVP-TMP *T*-1)))))))))))
     .))
( (S (NP-SBJ-1 (NP The high court 's)
	       action)
     ,
     (S-ADV (NP-SBJ-2 *)
	    (VP refusing
		(S (NP-SBJ *-2)
		   (VP to
		       (VP hear
			   (NP (NP appeals)
			       (PP by
				   (NP several drug companies))))))))
     ,
     (VP is
         (ADJP-PRD likely
		   (S (NP-SBJ *-1)
		      (VP to
			  (VP have
			      (NP a significant impact)
			      (PP-LOC at
				      (NP several levels)))))))
     .))
( (S (NP-SBJ The
             (ADJP most immediate)
             effect)
     (VP is
	 (PP-LOC-PRD in
		     (NP (NP New York)
			 ,
			 (SBAR-LOC (WHADVP-1 where)
				   (S (NP-SBJ (NP former manufacturers)
					      (PP of
						  (NP (NP the anti-miscarriage drug DES)
						      (PRN --
							   (NP the synthetic female hormone diethylstilbestrol)
							   --))))
				      (VP face
					  (NP (NP the prospect)
					      (PP of
						  (NP (NP shared liability)
						      (PP for
							  (NP damages)))))
					  (PP-LOC in
						  (NP (NP many)
						      (PP of
							  (NP (NP the
								  (QP 700 to 1,000)
								  DES lawsuits)
							      (VP pending
								  (PP-LOC in
									  (NP that state)))))))
					  (ADVP-LOC *T*-1)))))))
     .))
( (S (NP-SBJ The lawsuits)
     (VP stemmed
         (PP-CLR from
		 (NP (NP the development)
		     (PP of
			 (NP (NP cancer)
			     and
			     (NP other problems)))
		     (PP-LOC in
			     (NP (NP the daughters)
				 (PP of
				     (NP (NP women)
					 (SBAR (WHNP-1 who)
					       (S (NP-SBJ *T*-1)
						  (VP took
						      (NP the drug)))))))))))
     .))
( (S (PP On
         (NP a broader scale))
     ,
     (NP-SBJ the ruling)
     (VP could
         (VP encourage
	     (S (NP-SBJ (NP other states ')
			courts)
                (VP to
                    (VP adopt
                        (NP (NP the logic)
                            (PP of
                                (NP the New York court)))
                        ,
                        (PP-LOC (CONJP not only)
				(PP in
				    (NP DES cases))
				but
				(PP in
				    (NP other product-related lawsuits))
				,
				(ADVP as well)))))))
     .))
( (S (NP-SBJ The
	     (NAC New York Court
		  (PP of
		      (NP Appeals)))
	     ruling)
     (VP parallels
         (NP (NP a 1980 decision)
	     (PP by
		 (NP the California Supreme Court))
             (VP requiring
                 (NP (NP shared liability)
                     (PP among
                         (NP manufacturers))
                     (PP for
                         (NP injuries)))
                 (SBAR-TMP (WHADVP-3 when)
			   (S (NP-SBJ it)
			      (VP ca n't
				  (VP be
				      (VP determined
					  (SBAR (WHNP-2 which company)
						(S (NP-SBJ *T*-2)
						   (VP is
						       (PP-PRD at
							       (NP fault)))))
					  (ADVP-TMP *T*-3)))))))))
     .))
( (S (NP-SBJ (NP Paul Rheingold)
             ,
             (NP (NP a New York lawyer)
                 (SBAR (WHNP-1 who)
                       (S (NP-SBJ *T*-1)
                          (VP represents
                              (NP DES victims)))))
             ,)
     (VP said
         (SBAR that
               (S (PP-TMP before
			  (NP the New York ruling))
                  ,
                  (NP-SBJ (NP only the states)
                          (PP of
                              (NP Washington
                                  and
                                  Wisconsin)))
                  (VP had
                      (VP followed
                          (NP the California decision))))))
     .))
( (S (ADVP-TMP Now
	       (SBAR that
		     (S (NP-SBJ-1 the New York decision)
			(VP has
			    (VP been
				(VP left
				    (S (NP-SBJ *-1)
				       (ADJP-PRD intact))))))))
     ,
     (NP-SBJ other states)
     (VP may
         (VP follow
             (NP-CLR suit)))
     .))
( (SINV ``
	(S-TPC-1 (ADVP Generally)
		 ,
		 (SBAR-TMP (WHADVP-2 when)
			   (S (NP-SBJ (NP New York)
				      and
				      (NP California))
			      (VP go
				  (NP-DIR one way)
				  (ADVP-TMP *T*-2))))
		 ,
		 (NP-SBJ it)
		 (VP has
		     (NP (NP a tremendous influence)
			 (PP on
			     (NP (NP other states)
				 ,
				 (ADVP especially) 
				 (NP small ones))))))
	,
	''
	(VP said
	    (S *T*-1))
	(NP-SBJ Mr. Rheingold)
	.))
( (S (NP-SBJ-2 The high court)
     (VP refused
         (S (NP-SBJ *-2)
            (VP to
                (VP hear
                    (NP (NP appeals)
                        (PP by
                            (NP-LGS (NP Rexall Drug Co.)
				    ,
				    (SBAR (WHNP-1 which)
					  (S (NP-SBJ-3 *T*-1)
					     (VP (VP went
						     (PP-CLR out
							     (PP of
								 (NP business)))
						     (PP-TMP in
							     (NP 1987)))
						 and
						 (VP was
						     (VP taken
							 (NP *-3)
							 (PRT over)
							 (PP by
							     (NP-LGS (NP RXDC Liquidating Trust)
								     ;
								     (NP (NP E.R. Squibb & Sons Inc.)
									 ,
									 (NP (NP a unit)
									     (PP of
										 (NP Squibb Corp.))))
								     ; and
								     (NP Eli Lilly & Co)))))))))))))))
     .))
( (S (NP-SBJ The appeals)
     (VP involved
         (NP (NP DES)
             ,
             (SBAR (WHNP-2 which)
                   (S (NP-SBJ-1 *T*-2)
                      (VP was
                          (VP approved
                              (NP *-1)
                              (PP by
                                  (NP-LGS the Food and Drug Administration))
                              (PP-CLR for
				      (NP (NP use)
					  (PP-TMP (PP from
						      (NP the 1940s))
						  (PP until
						      (NP 1971)))
					  (S (NP-SBJ *) 
					     (VP to
						 (VP prevent
						     (NP miscarriages)
						     (PP-TMP during
							     (NP pregnancy)))))))))))))
     .))
( (S (PP-TMP In
	     (NP 1971))
     ,
     (NP-SBJ the FDA)
     (VP banned
	 (NP (NP the use)
	     (PP of
		 (NP DES)))
	 (SBAR-TMP after
		   (S (NP-SBJ studies)
		      (VP linked
			  (NP it)
			  (PP-CLR to
				  (NP (NP (NP cancer)
					  and
					  (NP other problems))
				      (PP-LOC in
					      (NP (NP daughters)
						  (PP of
						      (NP (NP women)
							  (SBAR (WHNP-1 who)
								(S (NP-SBJ *T*-1)
								   (VP took
								       (NP the drug))))))))))))))
     .))
( (S (NP-SBJ (NP Lawsuits)
             (PP over
                 (NP (NP the harm)
                     (VP caused
                         (NP *)
                         (PP by
                             (NP-LGS DES))))))
     (VP have
         (VP flooded
             (NP (UCP federal and state) courts)
             (PP-TMP in
		     (NP the past decade))))
     .))
( (S (PP-LOC In
	     (NP many cases))
     ,
     (S (NP-SBJ-1 the lawsuit)
	(VP was
	    (VP filed
		(NP *-1)
		(SBAR-TMP (ADVP long)
			  after
			  (S (NP-SBJ-2 the drug)
			     (VP was
				 (VP used
				     (NP *-2))))))))
     (PRN --
	  (S (NP-SBJ-4 (NP the cancer)
		       (PP-LOC in
			       (NP the daughters)))
	     (VP was
		 (ADVP typically)
		 not
		 (VP detected
		     (NP *-4)
		     (PP-TMP for
			     (NP years)))))
	  --)
     and
     (S (NP-SBJ there)
        (VP is
            (NP-PRD (NP no way)
		    (SBAR (WHADVP-5 0)
			  (S (NP-SBJ *)
			     (VP to
				 (VP prove
				     (SBAR (WHNP-3 (WHNP which)
						   (PP of
						       (NP several companies)))
					   (S (NP-SBJ *T*-3)
					      (VP manufactured
						  (NP (NP the doses)
						      (VP consumed
							  (NP *)
							  (PP by
							      (NP-LGS certain women)))))))
				     (ADVP-MNR *T*-5))))))))
     .))
( (S (PP-LOC Under
	     (NP traditional legal theories))
     ,
     (NP-SBJ inability
             (S (NP-SBJ *)
                (VP to
                    (VP prove
                        (SBAR (WHNP-1 which company)
			      (S (NP-SBJ *T*-1)
				 (VP manufactured
				     (NP (NP a drug)
					 (SBAR (WHNP-2 that)
					       (S (NP-SBJ *T*-2)
						  (VP caused
						      (NP an injury or death))))))))))))
     (VP would
         (VP lead
             (PP-CLR to
		     (S-NOM (NP-SBJ-3 the lawsuit)
			    (VP being
				(VP dismissed
				    (NP *-3)))))))
     .))
( (S But
     (PP-LOC in
	     (NP (NP its ruling)
		 (NP-TMP last April)))
     ,
     (NP-SBJ the New York court)
     (VP said
         (SBAR that
               (S (NP-SBJ (NP all producers)
			  (PP of
			      (NP the anti-miscarriage drug)))
		  (VP should
		      (VP share
			  (NP liability)
			  (SBAR-TMP (WHADVP-2 when)
				    (S (NP-SBJ-1 (NP the manufacturer)
						 (PP of
						     (NP a specific dose)))
				       (VP ca n't
					   (VP be
					       (VP determined
						   (NP *-1)
						   (ADVP-TMP *T*-2)))))))))))
     .))
( (S (NP-SBJ-1 (NP (NP Each company 's)
		   share)
               (PP of
                   (NP liability)))
     (VP would
         (VP be
             (VP based
                 (NP *-1)
                 (PP-CLR on
			 (NP (NP their share)
			     (PP of
				 (NP the national DES market)))))))
     .))
( (S (NP-SBJ The New York court)
     (ADVP also)
     (VP upheld
         (NP (NP a state law)
             ,
             (VP passed
                 (NP *)
                 (PP-TMP in
			 (NP 1986)))
             ,
             (VP extending
                 (PP-TMP for
			 (NP one year))
                 (NP (NP the statute)
                     (PP of
                         (NP limitations))
                     (PP on
                         (NP filing DES lawsuits))))))
     .))
( (S (NP-SBJ The effect)
     (VP is
         (SBAR-PRD that
		   (S (NP-SBJ (NP lawsuits)
			      (SBAR (WHNP-2 that)
				    (S (NP-SBJ-3 *T*-2)
				       (VP might
					   (VP have
					       (VP been
						   (VP barred
						       (NP *-3) 
						       (SBAR-PRP because
								 (S (NP-SBJ-1 they)
								    (VP were
									(VP filed
									    (NP *-1)
									    (ADVP-TMP too late))))))))))))
		      (VP could
			  (VP proceed
			      (PP-PRP because
				      of
				      (NP the one-year extension)))))))
     .))
( (NP -LRB-
      (NP (NP Rexall Drug Co.)
          (PP vs.
              (NP Tigue)))
      ;
      (NP (NP E.R. Squibb & Sons Inc.)
          (PP vs.
              (NP Hymowitz)))
      , and
      (NP (NP Eli Lilly & Co.)
          (PP vs.
              (NP Hymowitz)))
      -RRB-))
( (NP-HLN Government Contractors))
( (S (NP-SBJ-1 The high court)
     ,
     (S (NP-SBJ *-1)
	(VP leaving
	    (S (ADJP-PRD intact)
	       (NP-SBJ (NP a (ADJP (QP $ 4.25 million) *U*) damage award)
		       (PP against
			   (NP General Dynamics Corp.))))))
     ,
     (VP declined
         (S (NP-SBJ *-1)
            (VP to
                (VP resolve
                    (NP (NP questions)
			(PP about
			    (NP (NP a legal defense)
				(PP against
				    (NP civil lawsuits))
				(VP (ADVP-TMP often)
				    used
				    (NP *)
				    (PP by
					(NP-LGS government contractors))))))))))
     .))
( (S (NP-TMP Last year)
     ,
     (NP-SBJ the Supreme Court)
     (VP defined
         (SBAR (WHADVP-1 when)
               (S (NP-SBJ-2 (NP companies)
			    ,
			    (PP such
				as
				(NP military contractors))
			    ,)
                  (VP may
                      (VP defend
                          (NP themselves)
                          (PP-CLR against
				  (NP (NP lawsuits)
				      (PP for
					  (NP deaths or injuries))))
                          (PP-MNR by
				  (S-NOM (NP-SBJ *-2)
					 (VP asserting
					     (SBAR that
						   (S (NP-SBJ they)
						      (VP were
							  (VP (ADVP-MNR simply)
							      following
							      (NP (NP specifications)
								  (PP of
								      (NP a federal government contract))))))))))
			  (ADVP-TMP *T*-1))))))
     .))
( (S (PP-LOC In
	     (NP that decision))
     ,
     (NP-SBJ the high court)
     (VP said
         (SBAR 0
               (S (NP-SBJ a company)
                  (VP must
                      (VP prove
                          (SBAR (SBAR that
                                      (S (NP-SBJ the government)
                                         (VP approved
                                             (NP (NP precise specifications)
                                                 (PP for
                                                     (NP the contract))))))
                                ,
                                (SBAR that
                                      (S (NP-SBJ-1 those specifications)
                                         (VP were
                                             (VP met
                                                 (NP *-1)))))
                                and
                                (SBAR that
                                      (S (NP-SBJ-2 the government)
                                         (VP was
                                             (VP warned
                                                 (NP *-2)
                                                 (PP-CLR of
							 (NP (NP any dangers)
							     (PP in
								 (NP (NP use)
								     (PP of
									 (NP the equipment))))))))))))))))
     .))
( (S But
     (NP-TMP last February)
     ,
     (NP-SBJ-1 (NP a federal appeals court)
	       (PP-LOC in
		       (NP New Orleans)))
     (VP upheld
         (NP (NP a damage award)
             (PP against
                 (NP General Dynamics)))
	 ,
	 (S-ADV (NP-SBJ *-1)
		(VP rejecting
		    (NP (NP (NP the company 's)
			    use)
			(PP of
			    (NP the government contractor defense))))))
     .))
( (S (NP-SBJ The appeals court)
     (VP said
         (SBAR 0
               (S (NP-SBJ the defense)
                  (VP is
                      (ADJP-PRD valid)
		      (SBAR-ADV only if
				(S (NP-SBJ federal officials)
				   (VP (VP did
					   (NP (NP more)
					       (SBAR than
						     (S (NP-SBJ *)
							(VP rubber
							    stamp
							    (NP (NP a company 's)
								design or plans))))))
				       and
				       (VP engaged
					   (PP-CLR in
						   (NP (NP a `` substantive review and evaluation '')
						       (PP on
							   (NP (NP a par)
							       (PP with
								   (NP a policy decision))))))))))))))
     .))
( (S (NP-SBJ-1 General Dynamics)
     (VP appealed
         (PP-CLR to
		 (NP the high court))
         ,
         (S-ADV (NP-SBJ-2 *-1)
		(VP backed
		    (NP *-2)
		    (PP by
			(NP-LGS numerous business trade groups))))
         ,
         (S-ADV (NP-SBJ *-1)
		(VP arguing
		    (SBAR that
			  (S (NP-SBJ the appeals court definition)
			     (VP restricts
				 (NP the defense)
				 (ADVP-MNR too severely)))))))
     .))
( (S (NP-SBJ-1 General Dynamics)
     (VP was
         (VP sued
             (NP *-1)
             (PP by
                 (NP-LGS (NP the families)
			 (PP of
			     (NP (NP five Navy divers)
				 (SBAR (WHNP-3 who)
				       (S (NP-SBJ-2 *T*-3)
					  (VP were
					      (VP killed
						  (NP *-2)
						  (PP-TMP in
							  (NP 1982))
						  (SBAR-TMP after
							    (S (NP-SBJ they)
							       (VP re-entered
								   (NP a submarine)
								   (PP-DIR through 
									   (NP a diving chamber)))))))))))))))
     .))
( (S (NP-SBJ-1 The accident)
     (VP was
         (VP caused
             (NP *-1)
             (PP by
                 (NP-LGS (NP faulty operation)
			 (PP of
			     (NP a valve))))))
     .))
( (S (S (NP-SBJ A federal district court)
        (VP awarded
            (NP damages)
            (PP-DTV to
		    (NP the families))))
     and
     (S (NP-SBJ the appeals court)
        (VP affirmed
            (NP the award)))
     .))
( (NP -LRB-
      (NP General Dynamics Corp.)
      (PP vs.
	  (NP Trevino))))
( (NP-HLN (NP Court)
	  (PP in
	      (NP Brief))))
( (FRAG (PP-LOC In
		(NP other action))
	(NP-TMP yesterday)
	,
	(NP the high court)
	:))
( (FRAG --
	(VP Let
	    (S (VP stand)
	       (NP-SBJ (NP the mail fraud and conspiracy conviction)
		       (PP of
			   (NP (NP John Lavery)
			       ,
			       (NP (NP a former vice president)
				   (PP of
				       (NP (NP Beech-Nut Nutrition Corp.)
					   ,
					   (NP (NP a unit)
					       (PP of
						   (NP Nestle S.A)))))))))))
	.))
( (S (NP-SBJ The conviction)
     (VP stemmed
         (PP-CLR from
		 (NP (NP federal charges)
		     (PP of
			 (NP consumer fraud))
		     (PP for
			 (NP (NP sale)
			     (PP of
				 (NP phony infant apple juice))
			     (PP-TMP between
				     (NP 1978
					 and
					 1983)))))))
     .))
( (NP -LRB-
      (NP Lavery)
      (PP vs.
	  (NP U.S))
      . -RRB-))
( (FRAG --
	(VP Left
	    (S (ADJP-PRD intact)
	       (NP-SBJ (NP an award)
		       (PP of
			   (NP (NP (QP $ 1.5 million) *U*)
			       (PP in
				   (NP damages))))
		       (PP against
			   (NP Dow Chemical Co.))
		       (PP-LOC in
			       (NP (NP the death)
				   (PP of
				       (NP an Oregon man))
				   (PP from
				       (NP (NP exposure)
					   (PP to
					       (NP Agent Orange)))))))))
	.))
( (S (NP-SBJ-1 The award)
     (VP was
         (VP made
             (NP *-1)
             (PP by
                 (NP-LGS a federal court))
             (PP-CLR to
		     (NP (NP the widow)
			 (PP of
			     (NP (NP a U.S. Forest Service employee)
				 (SBAR (WHNP-2 who)
				       (S (NP-SBJ-3 *T*-2)
					  (VP contracted
					      (NP (NP Hodgkin 's)
						  disease)
					      (PP-TMP after
						      (S-NOM (NP-SBJ *-3)
							     (VP using
								 (NP (NP herbicides)
								     (VP containing
									 (NP Agent Orange)))
								 (PP-LOC in
									 (NP a weed-killing program))))))))))))))
     .))
